14-12-2012

Biotie reported top-line data from a Phase 2b study evaluating its adenosine A2a antagonist tozadenant (SYN115) in Parkinson's disease (PD) patients experiencing levodopa related end of dose wearing off. The study met its primary endpoint of a statistically highly significant decrease in ...

more

First patient treated with novel allergy vaccine

12-11-2012

Anergis reported that it has treated the first patient in a large, well-controlled Phase IIb clinical trial in individuals with birch pollen allergy. The trial is designed to evaluate the efficacy and tolerability of a 5-injection / 2- months treatment with Anergis´ lead allergy vaccine, ...

more

29-06-2012

Bioxyne Limited has received the preliminary analysis of the study 005 which examines the efficacy and safety of the immunotherapeutic, HI 164 OV in patients with chronic obstructive pulmonary disease (COPD).The study recruited 320 patients from 21 sites around Australia. At study’s end ...

more

12-06-2012

Photocure ASA announced the results of the phase 2b study in acne with Visonac (methyl aminolevulinate 80mg/g), a topical acne treatment. In this study, Visonac showed a statistically significant reduction in inflammatory lesions and overall improvement in acne severity.The phase 2b trial ...

more

05-09-2011

Hatchtech Pty Ltd has completed treatment of subjects for its Phase 2b clinical study to confirm the efficacy of its novel head lice treatment DeOvo™.This Phase 2b trial is evaluating the efficacy, safety and tolerability of two dose levels of a single application of DeOvo™ compared to ...

more

09-08-2011

The final patient has performed the last visit of the study period in Action Pharma’s US and Denmark based phase IIb study. Treatment with AP214 is designed to investigate whether acute kidney injury can be prevented in patients undergoing major cardiac surgery – a serious unmet medical need ...

more

Ponesimod to proceed to Phase III final stage of clinical development

03-08-2011

Actelion announced that the primary endpoint - reduction in the number of new active inflammatory lesions in the brain - has been met with its selective S1P1 receptor agonist, ponesimod, in a Phase IIb dose-finding study in patients with relapsing-remitting multiple sclerosis.The study ...

more

Data Published in GUT Shows Addex' ADX10059 Reduces GERD Symptoms in Patients

28-05-2009

Addex Pharmaceuticals is pioneering a new approach to the treatment of gastroesophageal reflux disease (GERD), a common disorder affecting approximately 15 percent of people. GERD is the cause of commonly recognized unpleasant symptoms like heartburn, acid brash and reflux. By inhibiting ...

more

05-07-2005

Pfizer Inc provided updates on two drug candidates in the company's development pipeline: Capravirine - Pfizer is discontinuing development of capravirine, a non-nucleoside reverse transcriptase inhibitor under study for patients with HIV/AIDS who have failed on currently available ...

more